CDKN2A and head and neck cancer: P16 protein expression is associated with improved survival among patients with OPSCC 6, and p16 immunostaining is used routinely in a clinical setting as a surrogate marker of HPV infection in OPSCC, but shows poor clinical utility in nonoropharyngeal head and neck cancers 7,8.